Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 18/20 | 0.55 |
| ▸ | DDR2 | Q16832 | 4/20 | 0.55 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.55 |
| ▸ | MAPK13 | O15264 | 8/20 | 0.53 |
| ▸ | MAPK12 | P53778 | 8/20 | 0.53 |
| ▸ | MAPK11 | Q15759 | 8/20 | 0.53 |
| ▸ | SRC | P12931 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5481591 | 0.95 | MAPK14 (0.59) | MAPK14DDR2MAPK9MAPK13MAPK12 | |
| SCHEMBL5480272 | 0.92 | MAPK14 (0.58) | MAPK14DDR2MAPK9MAPK13MAPK12 | |
| SCHEMBL5473558 | 0.88 | MAPK14 (0.52) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL5475317 | 0.87 | MAPK14 (0.53) | MAPK14DDR2MAPK9MAPK13MAPK12 | |
| SCHEMBL5476050 | 0.85 | MAPK14 (0.58) | MAPK14DDR2MAPK9MAPK13MAPK12 | |
| SCHEMBL1979544 | 0.84 | MAPK14 (0.59) | MAPK14DDR2MAPK9MAPK13MAPK12 | |
| SCHEMBL5476618 | 0.83 | MAPK14 (0.54) | MAPK14MAPK9MAPK13MAPK12MAPK11 | |
| SCHEMBL5486881 | 0.83 | MAPK14 (0.54) | MAPK14MAPK9MAPK13MAPK12MAPK11 | |
| SCHEMBL5474658 | 0.80 | POLB (0.44) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL5481694 | 0.80 | MAPK14 (0.50) | MAPK14MAPK13MAPK12MAPK11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070010529-A1 | Nitrogenous heterocyclic compounds and medical use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010529-A1 | Nitrogenous heterocyclic compounds and medical use thereof | MAPK1, NOS1, NOS2 | MAPK14 12/4885DDR2 4840/4885MAPK9 49/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.